Researchers have identified GPR133/ADGRD1, a mechanosensitive adhesion G protein-coupled receptor, as a promising therapeutic target for osteoporosis. The receptor responds to both mechanical forces and molecular signals, enhancing bone formation through cAMP-dependent activation of β-catenin signalling. A novel small-molecule agonist significantly alleviated osteoporosis in preclinical models, suggesting potential for clinical development.